Abstract
A global increase in the incidence of invasive group A streptococcal (iGAS) infections was observed after lifting COVID-19-related restrictions in 2022 with dominance of M1UK in many countries. After seasonal declines in iGAS incidence during the summer of 2023, simultaneous, rapid expansion of a previously rare emm type 3.93 was seen in both England and the Netherlands from November 2023, causing 20% and 60% of all iGAS cases, respectively, within 4 months. Emm3.93 was associated with iGAS in children 6-17 years of age and with increased risk of pneumonia/pleural empyema and meningitis in both countries. No significant excess risk of death was identified for emm3.93 compared to other types. Genomic analysis of historic and contemporary emm3.93 isolates revealed the emergence of three new clades with a previously undescribed genomic inversion. Our findings underscore the value of molecular surveillance, including long-read sequencing, in identifying clinical and public health threats.
Competing Interest Statement
NMvS reports fee for service and presentations from MSD, GSK and grants from the Dutch Health Council (ZonMW; all directly paid to the institution), contract research with Argenx (unrelated to this work), a patent on vaccine development against S. pyogenes (licensee: University of California San Diego, inventors Nina van Sorge and Victor Nizet; licensed by Vaxcyte; personal revenue), participation in the science advisory board of the ItsME foundation (no honorarium; https://itsme-foundation.com/en/) and Rapua te me ngaro ka tau, a project facilitating Strep A vaccine development for Aotearoa New Zealand (honorarium paid directly to the institution. A.P.v.D. reports a grant from Pfizer for a Borrelia vaccine study directly paid to the institution.
Funding Statement
This publication is part of the BEATGAS project (10150022310004), which was awarded to N.M.v.S, M.A.D, B.d.G, and B.J.M.V., and is financed by the Dutch Research Council (ZonMW) as part of the research programme Infectieziektebestrijding 3. This study was partly funded by the Dutch Ministry of Health, Welfare and Sport. For UKHSA, all work was performed as part of service delivery of the contributing authors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All studies were conducted in accordance with the European Statements for Good Clinical Practice and the Declaration of Helsinki of the World Medical Association. For the English data, Ethics committee of UK Health Security Agency waived ethical approval for this work based on legal permissions granted under Regulation 3 of the Health Service (Control of Patient Information) Regulations 2002. For the Netherlands, the Centre for Clinical Expertise at the RIVM (Center for Public Health and the Environment) verified whether this work complied with either the specific conditions as stated in article one of the Dutch law for Medical Research Involving Human Subjects (WMO) or with the EU Clinical Trial Directive (2001/20/EC), and was of the opinion that the research did not fulfill these conditions. Therefore, no formal ethical approval was required.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data underlying this article cannot be shared publicly due to patient confidentiality and deductive disclosure issues. Aggregated data will be shared on reasonable request to the corresponding author. Raw sequencing data and complete genomes are available from NCBI under the accession numbers listed in Supplementary File 1.
